Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
FDA approves Allergan’s Latisse
Irvine, Calif. - The Food and Drug Administration (FDA) has approved Latisse (bimatoprost ophthalmic solution)0.03 percent for the treatment of eyelash hypotrichosis, according to Allergan.
Irvine, Calif.
- The Food and Drug Administration (FDA) has approved Latisse (bimatoprost ophthalmic solution)0.03 percent for the treatment of eyelash hypotrichosis, according to Allergan.
Latisse will be the only FDA approved treatment to improve eyelash length, darkness and thickness, according to a press release.
Latisse will be available within the first quarter of 2009.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
